Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-01-12T20:48:50.376Z Has data issue: false hasContentIssue false
  • English
  • Français

Regulatory Issues Concerning Behavioral and Psychological Symptoms of Dementia: An Overview

Published online by Cambridge University Press:  10 January 2005

Peter J. Whitehouse
Peter J. Whitehouse
Affiliation:
Alzheimer Center University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA.
Get access

Extract

The global regulatory environment strongly affects the development of effective medications to treat behavioral and psychological symptoms of dementia (BPSD) (Whitehouse, 1998b). Since its inception in 1994, the International Working Group for Harmonization of Dementia Drug Guidelines (IWG) has been working to foster dialogue on dementia drug development among academics, regulators, industry representatives, and patients and their families. In this overview, I describe the IWG's mission, people, and recent activities (Whitehouse, 1998c), and its activities concerning BPSD in several regions throughout the world.

Type
Regulatory Issues
Information
International Psychogeriatrics , Volume 12 , Issue S1 , July 2000 , pp. 317 - 320
Copyright
© 2000 International Psychogeriatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)